AbCellera Biologics Inc.
ABCL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001703057
In the last 90 days, AbCellera Biologics Inc. insiders filed 3 open-market purchases and 0 sales; 152 institutions reported holding it in 13F filings for Q2 2026, worth $909.0M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:18 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $146.4M (194.9% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 27, 2025 | Feb 20, 2024 | Feb 21, 2023 | Feb 24, 2022 |
| Revenue | $75.1M | $28.8M | $38.0M | $485.4M | $375.2M |
| Operating expenses | $292.2M | $343.6M | $275.2M | $268.9M | $170.8M |
| Research and development | $186.8M | $167.3M | $175.7M | $107.9M | $62.1M |
| Selling, general and administrative | $83.2M | $72.7M | $61.0M | $55.5M | $41.8M |
| Operating income | -$217.1M | -$314.8M | -$237.2M | $216.5M | $204.4M |
| Income tax | -$31.2M | -$37.5M | -$27.6M | $80.6M | $65.7M |
| Net income | -$146.4M | -$162.9M | -$146.4M | $158.5M | $153.5M |
| EPS, basic | $-0.49 | $-0.55 | $-0.51 | $0.56 | $0.56 |
| EPS, diluted | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 |
| Weighted shares, basic | 298.7M | 294.3M | 289.2M | 285.1M | 275.8M |
| Weighted shares, diluted | 298.7M | 294.3M | 289.2M | 314.8M | 318.3M |
| Margins and growth | |||||
| Operating margin | -289.0% | -1091.7% | -623.8% | 44.6% | 54.5% |
| Net margin | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% |
| Revenue growth, year over year | +160.6% | −24.2% | −92.2% | +29.4% | – |
| Net income growth, year over year | – | – | −192.4% | +3.3% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 27, 2025 | Feb 20, 2024 | Feb 21, 2023 | Feb 24, 2022 |
| Cash and equivalents | $128.5M | $156.3M | $133.3M | $386.5M | $476.1M |
| Accounts receivable | $39.4M | $32.0M | – | – | – |
| Inventory | $6.34M | – | – | – | – |
| Total current assets | $728.2M | $751.4M | $872.0M | $1.03B | $929.8M |
| Property, plant and equipment | – | – | – | $217.3M | $111.6M |
| Goodwill | $47.8M | $47.8M | $47.8M | $47.8M | $47.8M |
| Intangible assets | $38.4M | $42.1M | $120.4M | $131.5M | $148.4M |
| Total assets | $1.36B | $1.36B | $1.49B | $1.54B | $1.32B |
| Total current liabilities | $64.3M | $76.6M | $119.0M | $118.3M | $120.7M |
| Total liabilities | $390.0M | $304.5M | $335.8M | $307.6M | $292.8M |
| Shareholders' equity | $966.9M | $1.06B | $1.15B | $1.23B | $1.03B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 27, 2025 | Feb 20, 2024 | Feb 21, 2023 | Feb 24, 2022 |
| Operating cash flow | -$131.3M | -$108.6M | -$43.9M | $277.4M | $244.6M |
| Capital expenditures | $42.8M | $78.4M | $76.9M | $70.7M | $58.5M |
| Free cash flow | -$174.1M | -$187.0M | -$120.8M | $206.7M | $186.1M |
| Depreciation and amortization | – | – | $24.4M | – | $14.5M |
| Stock-based compensation | $55.8M | $67.6M | $64.2M | $49.5M | $30.6M |
| Investing cash flow | $87.8M | $121.4M | -$221.1M | -$352.6M | -$332.2M |
| Financing cash flow | $14.1M | $12.8M | $10.4M | -$1.63M | -$3.89M |
| Net change in cash | -$28.4M | $23.0M | -$254.0M | -$86.5M | -$93.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 74.3% | 234.4% | 168.8% | 10.2% | 8.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 4, 2026 | 326.6M | +9.1% | SEC |
| Aug 3, 2026 | 306.6M | +2.6% | SEC |
| May 7, 2026 | 305.4M | +2.3% | SEC |
| Feb 19, 2026 | 303.2M | +1.7% | SEC |
| Nov 3, 2025 | 299.3M | +1.3% | SEC |
| Aug 4, 2025 | 298.8M | +1.4% | SEC |
| May 5, 2025 | 298.5M | +1.5% | SEC |
| Feb 21, 2025 | 298.0M | +1.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.